Seminars in Diagnostic Pathology
Volume 23, Issue 1 , Pages 35-43, February 2006

The biological differences between ovarian serous carcinoma and diffuse peritoneal malignant mesothelioma

  • Ben Davidson, MD, PhD

      Affiliations

    • Department of Pathology, Norwegian Radium Hospital-National Hospital, University of Oslo, Oslo, Norway
    • Corresponding Author InformationAddress reprint requests and correspondence: Ben Davidson, MD, PhD, Department of Pathology, The Norwegian Radium Hospital-National Hospital, Montebello N-0310 Oslo, Norway.
  • ,
  • Björn Risberg, MD, PhD

      Affiliations

    • Department of Pathology, Norwegian Radium Hospital-National Hospital, University of Oslo, Oslo, Norway
  • ,
  • Aasmund Berner, MD, PhD

      Affiliations

    • Department of Pathology, Norwegian Radium Hospital-National Hospital, University of Oslo, Oslo, Norway
  • ,
  • Carlos W.M. Bedrossian, MD, PhD (Hon), FIAC

      Affiliations

    • Department of Pathology, Norwegian American Hospital, Chicago, Illinois
  • ,
  • Reuven Reich, PhD

      Affiliations

    • R.R. is affiliated with the David R. Bloom Center for Pharmacy at the Hebrew University.
    • Department of Pharmacology and Experimental Therapeutics, School of Pharmacy, Faculty of Medicine, The Hebrew University of Jerusalem, Jerusalem, Israel.

Recent improvements in immunohistochemistry panels used for differentiating ovarian serous carcinoma/primary peritoneal carcinoma (OC/PPC) from diffuse malignant peritoneal mesothelioma (DMPM) have resulted in improved diagnostic rates for these tumors in both cytological and histological material. However, little is known about the biological characteristics that differentiate these two cancer types. We performed a comparative analysis of cancer-associated molecule expression data for a cohort consisting of up to 270 serous OC/PPC specimens (only peritoneal lesions) and 32 peritoneal MM. The molecules studied were nerve growth factor receptors (p75, p-TrkA), angiogenic factors (VEGF, IL-8, bFGF, heparanase), laminin receptors (the 67-kDa receptor and the α6 integrin subunit), proteases (MMP-2), immune response mediators (HLA-G), and signaling molecules (the MAPK members ERK, JNK, and p38). The methods used were immunohistochemistry, Western blotting, and RT-PCR. DMPM specimens showed significantly higher expression of p75 (P < 0.001), p-TrkA (P < 0.001), and bFGF (P < 0.001), and significantly lower expression of the 67-kDa receptor (P < 0.001), α6 integrin subunit (P = 0.025), VEGF (P < 0.001), IL-8 (P < 0.001), and HLA-G (P = 0.039) compared with OC/PPC. DMPM specimens showed higher activation ratio (phosphorylated/total enzyme ratio) of all three MAPK members (ERK, P = 0.017; JNK, P < 0.001; p38, P = 0.009) compared with OC/PPC. These data document significant differences in the expression of cancer- and metastasis-associated molecules in MM compared with ovarian carcinoma, and suggest that different biological pathways are involved in tumorigenesis and disease progression in these two tumors.

Keywords:  Ovarian carcinoma , Malignant mesothelioma , Effusions , Metastasis

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S0740-2570(06)00086-4

doi:10.1053/j.semdp.2006.06.003

Seminars in Diagnostic Pathology
Volume 23, Issue 1 , Pages 35-43, February 2006